Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 3Sarcoma 1Dermatologic 1

Conditions

Melanoma 3Waldenstrom Macroglobulinemia 2Sezary Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Mycosis Fungoides 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Lymphocytic, Chronic, B-Cell 2Immunoblastic Lymphadenopathy 2Burkitt Lymphoma 2Sarcoma, Synovial 1Ovarian Neoplasms 1Multiple Myeloma 1Leukemia, Large Granular Lymphocytic 1Leukemia, Hairy Cell 1Intraocular Lymphoma 1Hodgkin Disease 1Fallopian Tube Neoplasms 1

Interventions

pembrolizumab 28Cyclophosphamide 14Nivolumab 13Paclitaxel 7fludarabine 6Specimen Handling 5aldesleukin 4Taxes 4Ipilimumab 4Interleukin-2 4Gemcitabine 4Drug Therapy 4Docetaxel 4Carboplatin 4Bevacizumab 4poly ICLC 3liposomal doxorubicin 3epacadostat 3cobimetinib 3cemiplimab 3Magnetic Resonance Spectroscopy 3Injections 3Cisplatin 3veliparib 2ulixertinib 2sargramostim 2pertuzumab 2pegilodecakin 2pazopanib 2osimertinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Leukapheresis × Dermatologic × Clear all
NCT02650986 2025-06-17

Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

Roswell Park Cancer Institute

Phase 1/2 Active not recruiting
15 enrolled 12 charts
DermatologicGynecologicSarcoma

Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Synovial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡